There is a significant increase in dementia risk associated with the use of anticholinergic medications for three months or longer.

Serum phospho-tau217, a biomarker of tau protein that can be detected in the blood, is increased in preclinical Alzheimer’s disease and may have clinical utility for the early detection of brain pathology.

Individuals with Parkinson’s disease dementia and orthostatic hypotension (OH) showed more robust cognitive improvement from rivastigmine vs. those without OH. The anti-OH effect of rivastigmine probably mediates this better response.

Individuals with Parkinson’s disease dementia and orthostatic hypotension (OH) have more robust cognitive improvement from rivastigmine compared to those without OH. This greater response possibly is mediated by the anti-OH effect of rivastigmine.

Over a 36-month period, patients with prodromal Alzheimer’s disease who consumed Fortasyn Connect (Souvenaid), a nutraceutical drink, demonstrated a slower decline in cognitive functions vs. the control group.

In a randomized, double-blind, placebo-controlled trial of Fortasyn Connect (Souvenaid), a nutraceutical drink, patients with prodromal Alzheimer’s disease demonstrated, over a 36-month period, a slower decline in cognitive functions compared to the control group.

When most people think of the care continuum, they might imagine it as from the hospital to skilled nursing facilities to home, maybe with a primary care provider visit here and there. But that is not all, and case managers can use many more resources than those.

The proportion of Americans with Alzheimer’s disease and related dementias is expected to grow from 1.6% of the U.S. population in 2014 to 3.3% of the population in 2060. Case managers might see patients who have not been diagnosed with dementia forget their medications, or not eating, exercising, or sleeping well. Their family caregivers might say the patient is driving them crazy, but cannot explain any recent behavioral changes.